Does brexanolone work for postpartum depression in real practice?
Yes, in an uncontrolled real-world sample. Among 150 women treated with brexanolone, 68.7% achieved treatment response and 46.7% achieved remission posttreatment. At 12-month follow-up, 73.4% met response criteria and 60.9% met remission criteria. This is a real-world clinical report published in Women’s Health Reports describing 150 women with postpartum depression (mean age 30.0 years, SD 4.5) treated at a residential-style outpatient center, not a randomized controlled trial, so there is no comparison group. Benefits were sustained across 12 months of follow-up in a complex population, with 91.3% taking concomitant psychiatric medications.
Brexanolone is an FDA-approved infusion treatment for postpartum depression. It came out of basic science work showing that allopregnanolone, a neuroactive steroid and metabolite of progesterone, falls precipitously following childbirth.
What the data show:
- Depression symptoms: EPDS scores fell from 19.9 (SD 4.1) pretreatment to 10.5 (SD 4.5) posttreatment, p < 0.001, a within-group Cohen’s d of 2.2
- Treatment response: 68.7% posttreatment, 73.4% at 12 months
- Remission: 46.7% posttreatment, 60.9% at 12 months
- Anxiety: among a subset who had formal anxiety assessments, Perinatal Anxiety Screening Scale scores fell from 60.1 (SD 17.1) to 33.3 (SD 22.1), p < 0.01, within-group effect size 1.4
- Study scope: 150 women, with 91.3% on concomitant psychiatric medications and 31.3% on hormonal birth control
- Safety: among 15 participants with bipolar depression who were prescribed an antipsychotic or mood stabilizer, no episodes of mania or hypomania were reported during follow-up
The report describes outcomes in 150 women receiving brexanolone for postpartum depression in a clinical practice setting, with up to 12 months of follow-up.
Dr. Kumar’s Take
Controlled trials showed that brexanolone works under research conditions. This report tells me something different and, for my purposes, more useful: how it performs in the patients who actually walk into a clinic. Nine in ten of these women were already on other psychiatric medications, which is what real postpartum depression looks like, and the symptom improvement held across a year of follow-up. The absence of a control group means I cannot separate drug effect from natural recovery and intensive treatment-center care, and the 12-month numbers come from a retained subset, so attrition favors the people who stayed engaged. I read this as reassuring rather than definitive. The authors also connect these findings to zuranolone, the oral medication with a shared mechanism.
Study Snapshot
This real-world clinical report analyzed treatment outcomes in 150 women receiving brexanolone for postpartum depression at a residential-style outpatient treatment center. The sample had a mean age of 30.0 years (SD 4.5), with almost one-third (31.3%) on hormonal birth control and most (91.3%) taking concomitant psychiatric medications. Outcomes were tracked for up to 12 months after treatment. Fifteen participants carried a diagnosis of bipolar depression and were prescribed an antipsychotic or mood stabilizer at the time of treatment.
Results in Real Numbers
The sample included 150 women with postpartum depression, mean age 30.0 years (SD 4.5), treated at a residential-style outpatient treatment center. 91.3% were taking concomitant psychiatric medications and 31.3% were on hormonal birth control.
Depression scores dropped from a pretreatment mean EPDS of 19.9 (SD 4.1) to 10.5 (SD 4.5) posttreatment, p < 0.001, with a within-group effect size (Cohen’s d) of 2.2. That improvement held: among the 64 patients retained at 12 months, mean EPDS was 9.2 (SD 6.5), still significantly lower than baseline. 68.7% met response criteria posttreatment, rising to 73.4% at 12 months. 46.7% met remission criteria posttreatment, rising to 60.9% at 12 months.
Among a subset of participants who underwent formal anxiety assessments, Perinatal Anxiety Screening Scale scores fell from 60.1 (SD 17.1) pretreatment to 33.3 (SD 22.1) posttreatment, p < 0.01, with a within-group effect size of 1.4.
On safety, the 15 participants with bipolar depression who were prescribed an antipsychotic or mood stabilizer had no reported episodes of mania or hypomania during the follow-up period.
Who Benefits Most
These outcomes came from a population where the large majority were already on other psychiatric medications. Women treated in a residential-style outpatient setting showed improvement that persisted across 12 months.
Safety, Limits, and Caveats
This is an uncontrolled real-world report, not a randomized trial. Without a comparison group, improvement over time cannot be attributed to brexanolone alone, particularly given that most participants were on concurrent psychiatric medication and were receiving care in an intensive treatment setting.
Follow-up attrition matters. The 12-month EPDS scores come from a retained subset of 64 patients, and patients who remain in follow-up are not necessarily representative of those who drop out. The setting was a specialized residential-style treatment center, which may not generalize to all clinical environments, and outcomes beyond 12 months were not examined.
Practical Takeaways
- Concurrent psychiatric medication was the norm rather than the exception in this sample, so being on other treatments does not by itself rule out brexanolone
- Improvement in this cohort persisted through 12 months of follow-up, though only a subset of participants was still being tracked at that point
- Anxiety symptoms improved alongside depression symptoms in the subset formally assessed, which is relevant because postpartum anxiety often travels with postpartum depression
- Ask your clinician how the logistics and cost of an infusion compare with zuranolone, the oral medication that shares a mechanism with brexanolone
- Treat these results as supportive rather than conclusive when weighing options, since there was no control group
What This Means for Maternal Mental Health
Postpartum depression is underrecognized and undertreated, with as few as 5% of women treated to remission of symptoms, and untreated illness can persist for years. Against that backdrop, evidence that a treatment holds up outside controlled trial conditions carries real weight, even when it comes from an uncontrolled sample.
The authors also draw the line from these findings to zuranolone, the recently approved oral medication that shares brexanolone’s mechanism.
Related Studies and Research
Brexanolone Clinical Trials: Rapid Improvement in Postpartum Depression
Episode 31: Depression Explained, The Biology Behind the Darkness
Episode 32: Depression Recovery Roadmap: A Step-by-Step, Evidence-Based Plan
Role of HPA Axis in Depression Across Female Reproductive Lifecycle
FAQs
How long do brexanolone benefits last in real-world practice?
In this report, lower depression scores persisted through 12 months of follow-up among the 64 patients still being tracked at that point. Individual outcomes vary, and some patients may need additional treatment.
Can brexanolone work if I’m taking other psychiatric medications?
In this sample, 91.3% of participants were on concomitant psychiatric medications, and the group as a whole showed improvement sustained over 12 months.
Is brexanolone effective for complex cases of postpartum depression?
This report describes improvement in a population that included women on multiple psychiatric medications and 15 women with bipolar depression on an antipsychotic or mood stabilizer, none of whom had a reported manic or hypomanic episode during follow-up. There was no control group, so the results describe outcomes rather than prove causation.
Bottom Line
In 150 women treated at a residential-style outpatient center, brexanolone was associated with a large drop in depression scores, EPDS 19.9 to 10.5, with 68.7% response and 46.7% remission posttreatment and 73.4% response and 60.9% remission at 12 months among those retained. This is uncontrolled real-world data, so it supports rather than proves the treatment’s value, and the authors extend the relevance to zuranolone, the oral medication with the same mechanism.
